Compare PEPG & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEPG | ETON |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.3M | 683.7M |
| IPO Year | 2022 | 2018 |
| Metric | PEPG | ETON |
|---|---|---|
| Price | $1.69 | $26.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $11.17 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 2.3M | 468.4K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $1.01 | $13.09 |
| 52 Week High | $7.80 | $27.19 |
| Indicator | PEPG | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 21.03 | 72.12 |
| Support Level | $1.17 | $16.38 |
| Resistance Level | $5.46 | N/A |
| Average True Range (ATR) | 0.30 | 1.28 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 9.51 | 90.65 |
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.